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Abstract
Background: Skeletal muscle wasting is a debilitating consequence of large number of disease states and conditions. Tumor
necrosis factor-a (TNF-a) is one of the most important muscle-wasting cytokine, elevated levels of which cause significant
muscular abnormalities. However, the underpinning molecular mechanisms by which TNF-a causes skeletal muscle wasting
are less well-understood.
Methodology/Principal Findings: We have used microarray, quantitative real-time PCR (QRT-PCR), Western blot, and
bioinformatics tools to study the effects of TNF-a on various molecular pathways and gene networks in C2C12 cells (a
mouse myoblastic cell line). Microarray analyses of C2C12 myotubes treated with TNF-a (10 ng/ml) for 18h showed
differential expression of a number of genes involved in distinct molecular pathways. The genes involved in nuclear factor-
kappa B (NF-kappaB) signaling, 26s proteasome pathway, Notch1 signaling, and chemokine networks are the most
important ones affected by TNF-a. The expression of some of the genes in microarray dataset showed good correlation in
independent QRT-PCR and Western blot assays. Analysis of TNF-treated myotubes showed that TNF-a augments the activity
of both canonical and alternative NF-kB signaling pathways in myotubes. Bioinformatics analyses of microarray dataset
revealed that TNF-a affects the activity of several important pathways including those involved in oxidative stress, hepatic
fibrosis, mitochondrial dysfunction, cholesterol biosynthesis, and TGF-b signaling. Furthermore, TNF-a was found to affect
the gene networks related to drug metabolism, cell cycle, cancer, neurological disease, organismal injury, and abnormalities
in myotubes.
Conclusions: TNF-a regulates the expression of multiple genes involved in various toxic pathways which may be
responsible for TNF-induced muscle loss in catabolic conditions. Our study suggests that TNF-a activates both canonical and
alternative NF-kB signaling pathways in a time-dependent manner in skeletal muscle cells. The study provides novel insight
into the mechanisms of action of TNF-a in skeletal muscle cells.
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Introduction
Skeletal muscle atrophy or wasting is a common phenomenon
in a large number of systemic diseases including sepsis, diabetes,
chronic obstructive pulmonary disease, heart failure, and cancer
[1,2,3,4]. Accumulating evidence suggests that inflammatory
cytokines especially TNF-a play a major role in the development
of muscular abnormalities resulting in loss of skeletal muscle mass
and function [5]. Increased levels of TNF-a have been observed
under conditions that lead to skeletal muscle atrophy such as
chronic heart failure, cancer, AIDS, and cachexia induced by
bacteria [6]. TNF-a transduces its biological activities by binding
to two 55- and 75-kDa receptors [7]. Trimeric occupation of TNF
receptors by the ligand results in the recruitment of receptor-
specific proteins leading to the activation of a cascade of protein
kinases such as IkB kinase (IKK), transforming growth factor-b
activated kinase 1 (TAK1), mitogen-activated protein kinases
(MAPKs), and Akt and several downstream transcription factors
[7,8,9].
Nuclear factor-kappa B (NF-kB) is a major proinflammatory
transcription factor that regulates the expression of a plethora of
genes especially those involved in inflammatory and immune
responses [10,11]. Depending on the type of stimuli, the activation
of NF-kB can occur via either canonical or alternative pathway
[10]. The canonical NF-kB signaling pathway involves the
upstream activation of inhibitors of kB( I kB) kinase-b (IKKb)
and subsequent phosphorylation and degradation of IkB proteins.
On the other hand, activation of the alternative NF-kB pathway
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and IKKa and the proteolytic processing of p100 subunit into p52
[10,12]. Several recent studies have provided strong evidence that
constitutive activation of NF-kB leads to skeletal muscle wasting
and its inhibition prevents the loss of skeletal muscle mass in
response to various catabolic stimuli including TNF-a
[10,13,14,15,16,17]. Li et al [17] showed that TNF-a-induced
activation of NF-kB is responsible for the up-regulation of
ubiquitin-conjugating E2 enzyme UbcH2 resulting in increased
activity of ubiquitin-proteasome system and degradation of
myofibril proteins. Furthermore, the inhibitory effect of TNF-a
on myogenesis is mediated through the activation of NF-kB which
downregulates the levels of myogenic regulatory factor MyoD in
myoblasts through distinct mechanisms [18,19,20].
It is also noteworthy that the catabolic action of TNF-a in
skeletal muscle may require the presence of other proinflammatory
cytokines, such as TNF-related weak-inducer of apoptosis
(TWEAK), interleukin-1b (IL-1b), interleukin-6 (IL-6), and
interferon c (IFN-c) [16,21,22,23]. A combination of TNF-a
and IFN-c has been reported to cause a strong down-regulation of
muscle specific gene products including MyoD in cultured muscle
cells [18]. However, it is not yet clear whether TNF-a augments
the expression of other inflammatory cytokines or they are
expressed by independent mechanisms in skeletal muscle cells.
Recent investigations involving genome-wide gene expression
profiling in skeletal muscle has helped in identifying several novel
genes which mediate the loss of skeletal muscle mass in different
muscle-wasting conditions [24,25,26,27,28]. However, the effects
of TNF-a on the global gene expression and intracellular pathways
that it affects in skeletal muscle remain poorly understood. To
attain a better molecular insight into the mechanisms of action of
TNF-a in skeletal muscle, we focused the present investigation on
identification of TNF-regulated gene expression, gene networks,
and molecular pathways in skeletal muscle. Microarray analyses of
control and TNF-treated myotubes revealed that TNF-a regulates
the expression of several genes and pathways which may be related
to its catabolic action in skeletal muscle. Furthermore, our study
provides the initial evidence that TNF-a activates both canonical
and alternative NF-kB signaling pathways in skeletal muscle
cells.
Results
We have used microarray approach to identify the set of genes
which TNF-a regulates in cultured C2C12 myotubes. To detect
the expression of both early and late responsive genes, we have
performed mRNA profiling after 18h of TNF-a treatment.
Analysis using MTT [3-(4,5-dimethyl thiazol-2-yl)-2,5-diphenyl
tetrazolium bromide] dye showed no significant difference in cell
viability between control and TNF-treated C2C12 myotube
cultures after 18h (not depicted). Raw and normalized data of
this microarray experiment has been submitted to ArrayExpress
database (http://www.ebi.ac.uk/microarray-as/ae/) with acces-
sion number E-MEXP-2592.
Identification of differentially expressed genes in TNF-
treated C2C12 myotubes by microarray technique
C2C12 myotubes were treated with TNF-a (10ng/ml) for 18h
and the mRNA levels of different genes were monitored by
cDNA microarray technique. The microarray gene expression
profile appeared normally distributed for TNF-treated samples
(Figure 1A) indicating that our analyses of differentially expressed
genes is not biased due to skewed distribution of certain genes. Out
of approximately 25,000 genes present on our microarray chips,
TNF-a significantly (p,0.05) affected the expression of a total of
5,939 genes, out of which 3,349 genes were down regulated and
2,590 genes were up regulated. We have also filtered the genes
with the fold change $1.2 or #1.2, which yielded 1,822
differentially regulated genes. In particular, 723 genes were
significantly down regulated whereas 1,099 genes were signifi-
cantly up regulated by TNF treatment. The volcano plot of
differentially expressed genes with these cut-off p-values and fold
changes is presented in the Figure 1B. Further analysis of
differentially regulated genes showed that about 51 genes were
differentially regulated by TNF with p-values #0.0001 (28 up-
regulated and 23 down-regulated with fold values $1.2), 181
genes with p-value #0.001 (91 up-regulated and 90 down-
regulated), 751 genes with p-values #0.01 (406 up-regulated and
345 down-regulated), and 839 genes with p-values #0.05, of
which 574 genes were up-regulated and 265 genes were down-
regulated (Table 1). The functional annotations of important
genes differentially expressed in TNF-treated myotubes are
presented in the Table S1. Several genes such as transforming
growth factor beta 3 or TGF-b3( 21.28 fold), tissue inhibitor of
metalloproteinase 1 or TIMP1 (1.6 fold), nuclear factor of kappa
light chain gene enhancer in B-cells inhibitor, alpha or IkBa (3.98
fold), and chemokine (C-X-C motif) ligand 5 or Cxcl5 (8 fold) are
with p-values #0.0001. Genes such as inhibitor of DNA binding 3
or ID3 (21.63 fold), protein kinase inhibitor, alpha or PIKa
(21.38 fold), cyclin-dependent kinase inhibitor 1C or Cdkn1c
(21.3 fold), forkhead box d2 or FoxD2 (21.27 fold), nuclear factor
related to kappa B binding protein or NFRkB( 21.28 fold), B-cell
leukemia/lymphoma-6 or BCL6 (21.24 fold), jagged 2 or Jag2
(21.22 fold), vascular endothelial growth factor c or VEGFc (1.28
fold), insulin-like growth factor binding protein 7 or IGFbp7 (1.6
fold), tumor necrosis factor-alpha induced protein-3 or TNFaIP3
(1.6 fold), nuclear factor of kappa light chain gene enhancer in B-
cells 1, p105 or NFkB1 (1.6 fold), colony stimulating factor or
CSF1 (2-fold), chemokine (C-C motif) ligand 5 or Ccl5 (3.6 fold),
and chemokine (C-C motif) ligand 2 or Ccl2 (3.8 fold) were with p-
values #0.001. Among the genes with p-values #0.01, notch
homolog1 or Notch1 (21.6 fold), procollagen, type IV or Col4a2
(21.4 fold), early growth response 1 or EGR1 (21.3 fold),
adenylate cyclase 9 or Adcy9 (21.3 fold), insulin-like growth factor
binding protein-6 or IGFbp6 (21.25 fold), tumor necrosis factor
receptor superfamily, member23 or Tnfrsf23 (21.25 fold), fork-
head box O6 or FoxO6 (21.23 fold), TGF-b induced early growth
response 3 or Tieg3 (21.2 fold), signal transducer and activator of
transcription 5a or STAT5a (1.2 fold), tachykinin receptor 3 or
Tacr3 (91.2 fold), forkhead boxD3 or FoxD3 (1.23 fold), breast
cancer 1 or BRCA1 (1.27 fold), a disintegrin and metalloprotease
domain 29 or Adam29 (1.3 fold), cAMP response element binding
protein 3 or CREB3 (1.3 fold), myocyte enhancer factor 2B or
Mef2B (1.32 fold), Maf oncogene or v-maf (1.36 fold), chemokine
(C-X-C motif) receptor 3 or Cxcr3 (1.38 fold), nuclear factor of
kappa light polypeptide gene enhancer in B-cells 2, p49/100 or
NFkB2 (1.4 fold), matrix metalloproteinase-9 or MMP-9 (1.5 fold),
interleukin-6 or IL-6 (1.66 fold), and TAF2 RNA polymerase II,
TATA box binding protein (TAB)-associated factor, 150kDa (2.7
fold) are important genes regulating many pathways. Similarly,
myogenic differentiation 1 or MyoD1 (21.3 fold), mitogen
activated protein kinase 4 or MAPK4 (21.3 fold), myocyte
enhancer factor 2c or Mef2c (21.27 fold), CD27 binding protein
or Siva (21.24 fold), superoxide dismutase 1 or SOD1 (21.23
fold), Jun oncogene (21.2 fold), histone deacetylase 10 or
HDAC10 (21.2 fold), and vascular cell adhesion molecule 1 or
Vcam1 (2.91 fold) are very important genes differentially regulated
by TNF-a with p-values #0.05.
TNF-a Networks in Myotubes
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some of the genes which showed significant up- or down-
regulation in microarray experiment can be recapitulated in
independent quantitative real time-PCR (QRT-PCR) assays.
QRT-PCR assays were performed for the genes which showed
high fold change and/or have a direct or indirect relation with
skeletal muscle wasting. As shown in Figure 2A, the expression of
Nfkbia (also known as IkBa), Nfkb1, Nfkb2, IL-6, Vcam1, Ccl5,
Cxcl5, and Ccl2 was found to be significantly increased in TNF-
treated samples in QRT-PCR assays. Similarly, the reduced
expression of Notch1, TIMP2, and MyoD in TNF-treated samples
was confirmed by independent QRT-PCR assays (Figure 2B)
suggesting a direct correlation between microarray and QRT-
PCR analysis for almost all the genes tested.
C2C12 myoblasts differentiate into myotubes in low serum
conditions. However, the differentiation of C2C12 myoblasts into
myotubes is never complete [29]. C2C12 cultures incubated in
differentiation medium still contain a significant number of
undifferentiated myoblasts [29]. We investigated whether the
observed changes in gene expression in response to TNF-a occur
in undifferentiated myoblasts or myotubes or both in C2C12
cultures. To answer this question, we first studied whether TNF-a
can affect the gene expression in undifferentiated C2C12
myoblasts incubated in growth medium. Treatment with TNF-a
Figure 1. Gene distribution and volcano plots of differentially expressed genes in TNF-treated C2C12 myotubes. A) Distribution curve
of differentially expressed genes in response to TNF treatment detected by cDNA microarray analysis. The normalized fold changes were plotted on
y-axis on logarithmic scale. B) Volcano plots of differentially expressed genes in response to TNF treatment. Here 2log10 p-values were plotted on y-
axis and log2 values of normalized ratios were plotted on x-axis.
doi:10.1371/journal.pone.0013262.g001
Table 1. Number of differentially expressed genes with different p-values and $1.2 fold in TNF-a treated C2C12 myotubes.
p-value Up regulated genes Down regulated genes Total genes
#0.0001 28 23 51
.0.0001 but #0.001 91 90 181
.0.001 but #0.01 406 345 751
.0.01 to 0.05 574 265 839
doi:10.1371/journal.pone.0013262.t001
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VCAM-1 (Figure 3A) and reduced the levels of MyoD and
Notch1 (Figure 3B) in C2C12 myoblasts.
To evaluate whether TNF-a affects gene expression in myotubes,
we performed QRT-PCR assays for a few select genes using myosin
heavy chain 4 (MHC4, expressed only in differentiated muscles) as
the normalizing gene. The mRNA levels of NFKB1, NFKB2, and
VCAM-1 were significantly higher (Figure 4A) and that of MyoD
were significantly lower (Figure 4B) in TNF-treated cultures
compared to untreated cultures. Taken together, these results
indicate that TNF-a modulates gene expression in both myotubes
and myoblasts in a similar fashion.
In addition to TNF-a, several other proinflammatory cytokines
such as IL-1b and IL-6 have been postulated to be the mediators
of muscle-wasting in various chronic diseases [6]. We investigated
whether IL-1b and IL-6 can also modulate gene expression in
C2C12 cultures similar to TNF-a. Interestingly, we observed that
IL-1b but not IL-6 significantly augmented the expression of
NFKB1, NFKB2, and VCAM-1 in C2C12 cultures. However, the
fold increase in their mRNA levels in response to IL-1b was
significantly lower compared to TNF-a (Figure 4A). Moreover,
we found that while TNF-a significantly reduced mRNA level of
MyoD in C2C12 myotubes, neither IL-1b nor IL-6 had any
significant effect on the expression of MyoD (Figure 4B). The
Figure 2. Validation of genes differentially regulated by TNF-a by QRT-PCR. C2C12 myotubes were treated with 10 ng/ml of TNF for 18h
followed by isolation of total RNA and QRT-PCR. Untreated myotubes under similar conditions were taken as control. The relative expression values
(normalized with b-actin) from the QRT-PCR analysis were plotted for each gene are mean 6 SD (n=3). ‘*’ represents the statistical significance (p-
value #0.01). A). Data presented here show that mRNA levels of NFKB1, NFKB2, IkBa, IL-6, VCAM1, Ccl5, Cxcl5, and Ccl2 were significantly increased in
TNF-treated C2C12 cells. B). Data presented here show that mRNA levels of MyoD, Notch1, and Timp-2 were significantly reduced in TNF-treated
C2C12 myotubes.
doi:10.1371/journal.pone.0013262.g002
Figure 3. Effects of TNF-a on gene expression in C2C12 myoblasts. C2C12 myoblasts incubated in growth medium were treated with 10 ng/
ml TNF-a for 18h followed by isolation of total RNA and performing QRT-PCR assay. A). Data presented here demonstrate that TNF-a significantly
augments the expression of NFKB1, NFKB2, and VCAM-1 in C2C12 myoblasts. B). Data presented here demonstrate TNF-a significantly reduces the
mRNA levels of MyoD and Notch1 in C2C12 myoblasts. *p,0.05, values significantly different from control myoblasts incubated without TNF-a.
doi:10.1371/journal.pone.0013262.g003
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other cytokines may also contribute to muscle wastage to some
extent.
To further confirm our microarray findings, we also performed
Western blots for a few select proteins affected by TNF-a.
Consistent with their mRNA levels, the protein levels of NFKB1,
NFKB2, and MMP-9 were significantly increased in TNF-treated
myotubes compared to untreated myotubes (Figures 5A and
5B). It was interesting to note that while TNF-a increased the
mRNA levels of NFKB1 by ,15 fold, the increase in NFKB1
protein level was only ,1.6 fold (Figures 5A and 5B). Although
the exact reasons remain unknown, it is possible that in addition to
increasing the expression, TNF-a also increases the turnover of
NFKB1 protein. Furthermore, there is also a possibility that
NFKB1 mRNA is subjected to post-transcriptional modifications
(including those involving micro RNAs) which may limit its
translation into protein. In contrast to mRNA levels, the protein
levels of NF-kB inhibitor IkBa was found to be significantly
reduced (Figures 5A and 5B). The reduced levels of IkBa in
TNF -treated myotubes could be attributed to its enhanced
degradation in response to NF-kB activation stimuli [10,12]. In
agreement with microarray data, we found reduced protein levels
of Notch1 and TIMP-2 in TNF-treated myotubes (Figures 5C,
and 5D).
TNF-a causes activation of both canonical and alternative
NF-kB signaling pathways in myotubes
TNF-a is a well-known activator of canonical NF-kB signaling
pathway which involves the upstream activation of IkB kinase-b
(IKKb) and subsequent phosphorylation and degradation of IkBa
protein [7]. Although it has been reported that TNF-a activates
NF-kB in skeletal muscle cells [7,10,17,30], there has been no
report whether TNF-a can augment the activation of alternative
NF-kB signaling pathway which involves the activation of IKKa
and proteolytic processing of p100 subunit into p52. Surprisingly,
our microarray and subsequent QRT-PCR and Western blot
revealed increased expression of both NFKB1 (e.g. p105/p50) and
NFKB2 (e.g. p100/p52) in TNF-treated myotubes (Figures 2, 4,
and 5). These results prompted us to investigate whether TNF-a
activates both canonical and alternative NF-kB pathways and the
time points at which these two pathways are up-regulated after
treatment with TNF-a. C2C12 myotubes were treated with TNF-
a for different time periods ranging from 0–24h and the activation
of NF-kB was measured by electrophoretic mobility shift assays
(EMSA). As shown in Figure 6A, treatment with TNF-a led to
sustained activation of NF-kB in C2C12 myotubes though it
peaked at 1h, 6h and 18h. These results are consistent with a
previously published report also demonstrating biphasic activation
of NF-kB in C2C12 myotubes upon TNF-a-treatment [31]. To
investigate whether TNF-a-induced activation involves canonical,
alternative, or both pathways, we performed Western blot using
TNF-a-treated myotubes. As shown in Figure 6B, treatment with
TNF-a increased the phosphorylation and reduced the levels of
IkBa protein. IkBa protein levels remained lower compared to
untreated cultures indicating that TNF-a stimulates the canonical
NF-kB signaling pathway in myotubes. Interestingly, we found
that TNF-a did not affect the expression or proteolytic processing
of p100 subunit into p52 up to 6h. However, after 6h, a significant
increase was noticed in protein levels of both p100 and p52
suggesting the activation of alternative NF-kB pathway. IKKa is
the kinase which phosphorylates p100 protein leading to its
proteolytic processing into p52 subunit [10]. To further investigate
whether the activation of IKKa is increased in response to TNF-a
treatment, we performed Western blot using antibody which
recognizes the phosphorylated (activated) IKKa protein. As shown
Figure 4. Effects of TNF-a, IL-1b, and IL-6 on gene expression in C2C12 myotubes. C2C12 myotubes were treated with 10 ng/ml TNF-a, IL-
1b, or IL-6 for 18h followed by total RNA isolation and performing QRT-PCR using myosin heavy chain 4 (MYH4) as the normalizing gene. A). The fold
increase in mRNA levels of NFKB1, NFKB2, and VCAM-1 compared to untreated controls is presented here. B). Fold change in mRNA levels of MyoD
compared to untreated controls. *p,0.01, values significantly different from untreated myotubes.
#p,0.01, values significantly different from TNF-
treated myotubes for respective gene.
doi:10.1371/journal.pone.0013262.g004
TNF-a Networks in Myotubes
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dependent manner. Consistent with proteolytic degradation of
p100 protein, the activation of IKKa was noticeable at 12h and
later time points (Figure 6B).
To further confirm that TNF-a activates both canonical and
alternative NF-kB signaling pathways, we also performed super-
shift assays using nuclear extracts from TNF-treated myotubes. As
shown in Figure 6C, incubation of nuclear-extracts from 1h and
18h TNF-treated myotubes with anti-p50 and anti-p65 shifted the
NF-kB/DNA complex to higher molecular weight indicating that
activated NF-kB complex contains p50 and p65 (the components
of canonical NF-kB pathway) proteins. Although a slight shift was
observed with antibodies against RelB and p52 at 18h, a
remarkable increase in shifted bands was evident with both the
antibodies at 24h and 36h after treatment with TNF-a. These
results suggest that TNF-a initially activates canonical NF-kB
pathway followed by the activation of alternative pathway.
We have recently reported that TWEAK, a member of TNF
super family, is a potent activator of alternative NF-kB signaling
pathway in skeletal muscle cells [32]. By performing QRT-PCR,
we investigated whether TNF-a augments the expression of
TWEAK or its receptor Fn14 in C2C12 myotubes. Our results
showed that the mRNA levels of TWEAK were comparable
between control and TNF-treated myotubes (Figure 6D). Fur-
thermore, we could not detect TWEAK protein in culture
supernatants of control or TNF-treated myotubes by ELISA.
However, QRT-PCR assays showed a moderate increase (,1.7
fold) in the mRNA levels of Fn14 in TNF-treated myotubes
(Figure 6D).
Although TNF-a was found to stimulate alternative NF-kB
pathway, it was not clear whether TNF-a by itself is sufficient or
other cytokines, chemokines, and growth factors produced in
culture supernatants are responsible for the activation of
alternative NF-kB pathway in TNF-treated myotubes. To address
this issue, C2C12 myotubes were initially incubated with TNF-a
for 9h, the medium of the cells was replaced with fresh
differentiation medium (without TNF-a), and the cultures were
incubated for additional 9h. In a parallel culture, C2C12
myotubes were continuously treated with TNF-a for 18h. At the
end of the incubation period, the cells were collected and Western
blot was performed using p100/p52 antibody. As shown in
Figure 7A, TNF-a increased the levels of p100 and p52 protein in
both the cultures (i.e. those incubated with TNF-a for 9h or 18h).
Furthermore, we found that IL-1b (another inflammatory
cytokine) activated classical NF-kB pathway evident by degrada-
tion of IkBa protein (at 30 min and 1h) but did not affect the
protein levels of p100/p52 in C2C12 cultures (Figure 7B).
Collectively, these results suggest that TNF-a alone may be
sufficient to activate both classical and alternative pathways in
C2C12 myotubes.
Effect of TNF-a on various canonical pathways in C2C12
myotubes
Although TNF-a was found to differentially regulate the
expression of a large number of genes, it was not clear how the
expression of these genes affect the activity of various cellular and
molecular pathways in skeletal muscle cells. To understand the
effects of TNF on various canonical pathways, we used Ingenuity
Pathway Analysis (IPA) software. We first used a set of
differentially regulated genes with fold values $1.5 and p-value
of #0.05 from microarray analyses as an input for IPA software.
However, this set of genes was not sufficient to generate pathways
affected by TNF-a. We then reduced the stringency and used the
set of genes with fold change (both up- and down-regulated genes)
values $1.2 and p-value of #0.05 in the microarray experiment.
We found that TNF-a affected the expression of genes involved in
specific molecular pathways in myotubes (Figure 8). The major
pathways affected by TNF-a in myotubes were those that regulate
hepatic fibrosis, LXR/RXR activity, oxidative stress, mitochon-
drial dysfunction, and TGF-b and NF-kB signaling (Figure 8).
Figure 5. Western blot analyses of genes differentially expressed by TNF-a in myotubes. C2C12 myotubes were treated with 10 ng/ml of
TNF for 18h followed by isolation of total protein and Western blotting. Equal amounts of proteins were loaded on 10% SDS-PAGE gel.
A). Representative immunoblots presented here show that TNF-a increases the protein levels of NFKB1, NFKB2, MMP-9, and IkBa in myotubes.
B). Densitometry analyses of bands from NFKB1, NFKB2, MMP-9, and IkBa immunoblots. C). Protein levels of Timp-2 and Notch1 were found to be
reduced upon treatment with TNF-a. D). Densitometry analyses of bands from TIMP-2 and Notch1 immunoblots. *p,0.05, values significantly
different from corresponding control myoblasts incubated without TNF-a (n=4 in each group).
doi:10.1371/journal.pone.0013262.g005
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differentially regulated genes is consistent with the experimental
evidence that skeletal muscle-wasting and other muscular disorders
such as muscular dystrophy, involve the activation of many of
these molecular pathways [6,10,11,33,34].
TNF-a regulates distinct gene networks in myotubes
In order to understand the interaction between different genes,
we generated common networks using Ingenuity Pathway Analysis
(IPA) software. The dataset of differentially expressed genes by
TNF in C2C12 myotubes with selected stringency (p value #0.05
and fold $1.2) was uploaded into the IPA software tool. Networks
of these genes were then algorithmically generated based on their
connectivity. The graphical representation of the molecular
relationships between genes developed by IPA is presented in
Figure 9 and Figure 10. Based on the input information, the
genes that are down-regulated are shown in green and the up-
regulated genes are shown in red (Figure 9 and Figure 10).
Cytokines, growth factors and oxidative stress enzymes such as
TWEAK, IL-6, IGF binding protein (IGFBP), and SOD were
found to be involved in the network related to drug metabolism,
neurological disease, organismal injury and abnormalities
(Figure 9). This network also showed that many of these genes
are regulated by each other either directly or indirectly.
Furthermore, the networks related to cell cycle, cancer and
nervous system development and function showed that several
genes such as Nfkb2, NFkBia, BRCA1, Vegf, Jag2, Notch1,
EGR1, FoxS1 and collagen type I were regulated by TNF
(Figure 10).
Discussion
Although there is significant amount of literature suggesting the
role of TNF-a in skeletal muscle wasting [3,35,36,37,38], the
molecular mechanisms by which TNF-a induces muscle loss
remain poorly understood. In this study, we have employed
combination of microarray, bioinformatics tools, and biochemical
techniques to identify potential mechanisms by which TNF-a
might be regulating skeletal muscle mass.
TNF-a induces the expression of several cytokines,
chemokines, protein kinases, and transcriptional factors
in cultured myotubes
The microarray analysis of TNF-treated C2C12 myotubes
revealed that a total of 723 genes were significantly down
regulated and 1,099 genes were significantly up regulated by
TNF treatment with a p-value #0.05 and fold values of $1.2.
Among the significantly up-regulated genes CXCL5 (8-fold),
Figure 6. TNF-a activates canonical and alternative NF-kB pathways in C2C12 myotubes. A) C2C12 myotubes were treated with 10 ng/ml
of TNF for indicated time periods and the activation of NF-kB was measured by EMSA. The representative EMSA gel presented here shows that there
is a significant increase in NF-kB activity in myotubes upon treatment with TNF-a. B) C2C12 myotubes were treated with 10 ng/ml of TNF-a for
indicated time followed by performing Western blots using anti-IkBa, anti-p100/52, and anti-phospho-IKKa. C). Analysis of NF-kB/DNA complex by
super shift assays in myotubes treated with TNF-a for different lengths of time. D). The relative expression of TWEAK and Fn14 in control and TNF-
treated myotubes determined by QRT-PCR. *p,0.05, values significantly different from untreated myotubes.
doi:10.1371/journal.pone.0013262.g006
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fold), Taf2 (2.7-fold), Csf1 (2-fold), IL-6 (1.7-fold), Tnfaip3 or A20
(1.6-fold), MMP9 (1.5-fold), NFkB2 (1.4-fold), Traf5 (1.4-fold),
TWEAK (1.4-fold), CXCR3 (1.37-fold), VEGF(1.28-fold), Brca1
(1.27-fold) and Creb5 (1.24-fold) are the genes having either direct
or indirect role in many pathways induced by TNF-a. Infiltration
of leukocytes is a characteristic feature of acute inflammatory
condition which is found in many secondary myopathies. A study
on large selection of alpha/beta-chemokines and their receptors in
normal controls and in the inflammatory myopathies showed a
general increase of specific chemokines and chemokine receptors
[39]. An increase in expression levels of these chemokines and
induction of neutrophil influx have been previously reported upon
injection of TNF-a [40]. A recent study by Vieira et al [41]
showed that intraperitoneal injection of KC/CXCL1 and LIX/
CXCL5 induces dose and time-dependent neutrophil recruitment
and TNF-a production. Consistent with these published reports,
our microarray data show increased expression of many
chemokine ligands and their receptors, especially, Cxcl5 which is
up-regulated by 8-fold. The validation by QRT-PCR further
confirmed the up-regulation of these chemokine networks by
TNF-a (Figure 2A). These observations suggest that TNF-a
induces the expression of chemokines and their receptors, leading
to acute inflammation and myopathy.
Vascular cell adhesion molecule-1 (VCAM1), also known as
CD106, is expressed in a number of tissues including skeletal
muscle and its expression is increased in response to proinflam-
matory cytokines. It is one of the important target genes of NF-kB
transcription factor [12]. The VCAM-1 protein mediates the
adhesion of lymphocytes, monocytes, eosinophils, and basophils to
different tissues. It also functions in leukocyte-endothelial cell
signal transduction, and it may play a role in the development of
atherosclerosis and rheumatoid arthritis. Recent studies of Do et
al. [42] on microarray analysis of TNF treated human SGBS
adipocytes also reveal the up-regulation of this inflammatory gene.
Consistent with these studies, our microarray analysis of TNF-
treated myotubes showed increased expression of VCAM1, which
was further validated by QRT-PCR (Figures 2A and 4A).
Interleukin IL-6 is an important cytokine which acts as both
pro-inflammatory and anti-inflammatory molecule. This cytokine
is also called as ‘myokine’ because it is also expressed by skeletal
muscle and its levels are elevated during muscle contraction [43].
In one study, enhanced gene expression of IL-6 and decreased
levels of insulin signaling pathway and Akt pathway was observed
when enterocytes were treated with TNF-a [44]. Similar findings
were observed in an independent study, where the infusion of
angiotenisn II (AngII) increased circulating IL-6 in mice and
triggered protein degradation via suppression of insulin signaling
[45]. Our experiments demonstrate that TNF-a induces the
expression of IL-6 in myotubes (Figure 2A) suggesting that TNF-
a may also function through augmenting IL-6 expression to
further accelerate inflammation and protein degradation in
skeletal muscle.
TNF suppresses the expression of genes involved in
myogenesis, regeneration and ubiquitin proteasomal
degradation
Our oligonucleotide microarray analyses of TNF-treated
myotubes showed significant down-regulation of many important
genes such as inhibitor of DNA binding 3 (21.63-fold), Notch1
(21.57-fold), FGF21 (21.4-fold), procollagen type IV (21.4-fold),
phosphoglycerate mutase2 (21.4-fold), protein kinase inhibitor,
alpha (21.38-fold), Myod1 (21.3-fold), Smad6 (21.3-fold),
Mapk4 (21.3-fold), Tgfb3( 2.127-fold), FoxD2 (2.127-fold),
adenylate cyclase 9 (21.27-fold), Mef2c (21.27-fold), Insulin-like
5( 21.26-fold), Timp2 (21.26-fold), Jagged 2 (21.22-fold), Sod1
(21.22-fold), Jun (21.21-fold), and Tgfb inducible early growth
response (2.12-fold).
Recent studies have demonstrated that myogenic transcription
factors such as serum response factor (SRF), MEF2c, and MyoD
control the expression of myomiRs in skeletal and cardiac muscles
[46]. Our microarray experiment showed that TNF-a inhibits the
expression of MEF2c and MyoD transcription factors in cultured
myotubes (Table S1). We have previously demonstrated that
TWEAK reduces the levels of MyoD and myogenin in
differentiating C2C12 cultures [47]. We have also shown that
TWEAK down-regulates the expression levels of MEF2C in both
microarray as well as QRT-PCR in C2C12 myotubes [28]. In
correlation with these observations, we have also shown that
TWEAK down-regulates the myomiRs regulated by MEF2c
including miR-1, 133 and 206 [28]. The microarray analysis of
TNF-treated myotubes in the present study showed a significant
reduction in MEF2c and MyoD. The down-regulation of MyoD
was further confirmed by QRT-PCR (Figures 2A and 4B).
From these observations, we can speculate that similar to
Figure 7. Role of TNF-a and IL-1b in the activation of alternative
NF-kB signaling pathway. A). C2C12 myotubes were incubated with
or without TNF-a (10 ng/ml) continuously for 18h or for only 9h
followed by changing the medium with fresh differentiation medium
without TNF-a and incubation for additional 9h. The cell lysate made
were analyzed by Western blotting for p100/p52 protein. A represen-
tative immunoblot presented here demonstrate that removal of TNF-a
after 9h did not affect the TNF-induced expression/processing of p100/
p52 proteins. B). C2C12 myoblasts were treated with IL-1b (10 ng/ml)
for indicated time periods and the levels of p100/p52 and IkBa protein
were measured by Western blot. Data presented here show that IL-1b
induced the degradation of IkBa protein (after 30 min and 1h) but did
not affect the levels of either p100 or p52 proteins. TNF-a or IL-1b did
not affect the levels of an unrelated protein tubulin in C2C12 cultures.
doi:10.1371/journal.pone.0013262.g007
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down-regulation of specific myogenic regulatory factors and
thereby inhibiting the expression of various MyomiRs (miR-1,
133 and 206). These possibilities will be investigated in future
studies.
We also observed down-regulation of an antioxidant enzyme,
superoxide dismutase 1 (SOD1). SOD1 is a well-known player of
the anti-oxidative defense. The direct evidence of SOD1 in
muscular atrophy was recently reported by Muller et al. [48],
where they showed a dramatic increase in mitochondrial reactive
oxygen species (ROS) in three conditions of muscular atrophy in
animals lacking Sod1. In another study, mutations in Sod1gene
(SOD1
G93A) selectively in skeletal muscle showed progressive
muscle atrophy with concomitant reduction in muscle strength,
alterations in contractile apparatus, and mitochondrial dysfunction
[49]. In this study they also analyzed the molecular pathways
associated with muscle atrophy by Sod1 mutation and found that
accumulation of oxidative stress initiated autophagy and thereby
degradation of muscles. This suggests that skeletal muscle is the
primary target of Sod1 mutation-mediated toxicity whereby
oxidative stress triggers muscle atrophy. The down-regulation of
this important antioxidant in response to TNF-a treatment in our
microarray data suggests a possible link between the regulation of
Sod1 and TNF-induced muscular atrophy.
Another important gene that was significantly down-regulated
by TNF and is worth mentioning is Notch1. Notch-1 receptors are
transmembrane proteins which are expressed in a broad range of
tissues and function in diverse developmental and cell maturation
processes [50,51]. The intracellular regions of Notch receptors
contain several functional motifs: ankyrin/CDC10 repeats, RAM,
nuclear localization signals (NLS), PEST sequences, and a
glutamine-rich domain [50]. Ligands such as Delta or Jagged/
Serrate induce a second cleavage that requires presenilins at a site
within the transmembrane region of Notch [52,53] leading to
release of the intracellular fragment of Notch, which binds to
numerous nuclear and cytoplasmic proteins. Besides its role in
regulation of the activity of other transcription factors, recent
studies have shown that constitutively expressed Notch-1 functions
as a novel IkB-like molecule and regulates NF-kB-mediated gene
expression through a direct interaction with the NFkB1 (i.e. p50)
subunit [54,55]. This interaction prevents NF-kB from binding to
NF-kB recognition sites in DNA to regulate NF-kB-dependent
Figure 8. Differentially expressed genes associated with canonical pathway in the Ingenuity Pathway Analysis (IPA). Top canonical
pathways affected by TNF-a treatment were identified by using IPA analysis. Here the differentially regulated genes with p-value #0.05 and fold
change $1.2 were considered for IPA analysis. Bars represent 2log p-value and percentage of genes present in the data set compared to the total
number of genes present in each selected pathway in IPA data base. The yellow line represents 2log p-value of affected genes to the total number of
genes in a pathway. Each bar was represented in two different colors in which red correspond to the up-regulated genes and green corresponds to
down-regulated genes. The percentage of up-regulated and down-regulated genes in each selected canonical pathway can be measured in
percentage scale given on y-axis (left side).
doi:10.1371/journal.pone.0013262.g008
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PLoS ONE | www.plosone.org 9 October 2010 | Volume 5 | Issue 10 | e13262Figure 9. Network of genes involved in neurological disease and organismal injury in TNF-treated myotubes. The gene network
presented here was adopted from Ingenuity pathway analysis tool with differentially regulated genes by TNF-a with p-values #0.05 and $1.2-fold.
The solid lines connecting molecules here represent a direct relation and dotted lines an indirect relation. The genes shown in red are up-regulated
whereas down-regulated genes are shown in green color.
doi:10.1371/journal.pone.0013262.g009
Figure 10. TNF-a regulates gene networks involved in nervous system development, cell cycle and cancer. Schematic representation of
gene network obtained from Ingenuity pathway analysis tool with differentially regulated genes by TNF-a with p-values #0.05 and $1.2-fold. The
solid lines connecting molecules here represent a direct relation and dotted lines are representation of an indirect relation. The genes shown in red
color boxes are those which are up-regulated whereas down-regulated genes are shown in green color boxes.
doi:10.1371/journal.pone.0013262.g010
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(Figures 2B and 5C) may be responsible, at least in part, for
sustained activation of NF-kB in skeletal muscle cells in response to
TNF-a.
TNF-a induces the activation of both canonical and
alternative NF-kB signaling pathways in myotubes
Accumulating evidence strongly suggests that NF-kB is one the
most important signaling pathways, the activation of which leads
to skeletal muscle wastage [10]. NF-kB activation can occur
through two parallel pathways. The canonical NF-kB signaling
pathway involves the upstream activation of IkB kinase-b (IKKb)
and subsequent phosphorylation and degradation of IkB proteins
[56,57,58]. In contrast, the activation of the alternative NF-kB
pathway requires the upstream activation of NF-kB-inducing
kinase (NIK or MAP3K14) and IKKa and the proteolytic
processing of NFkB2 (p100 subunit) into p52 protein [57,58].
Previous studies from our group and other laboratories have
demonstrated that TWEAK increases the activation of both
canonical and alternative NF-kB pathways [32,59]. However,
there has been no report on the activation of alternative NF-kB
pathway by TNF-a in skeletal muscle. The microarray analysis in
the present study showed that TNF-a increases the expression
levels of both NFkB1 and NFkB2 in skeletal muscle cells
(Figures 2A, 3A, 4A, 5A, and 6B). We also performed Western
blots and EMSA and super-shift assays with radio-labeled NF-kB
at different time points after the addition of TNF-a in cultured
myotubes. These experiments demonstrated that TNF-a induces
NF-kB activity via canonical pathway initially (Figure 6B).
However a time-dependent increase in the components of
alternative pathway was observed at later time points. These
include the phosphorylation of IKKa, proteolytic degradation of
p100 into p52 (Figure 6B), and presence of p52 and RelB
subunits in NF-kB/DNA complex in super shift assays
(Figure 6C). Since the activation of alternative pathway persisted
even upon removal of TNF-a from culture medium after 9h
(Figure 7A), these observations suggest that TNF-a alone might
provide sufficient signal to activate alternative NF-kB pathway in
skeletal muscle. It is also noteworthy that the activation of
alternative NF-kB pathway in myotubes may be specific to TNF-a
and TWEAK. This inference is supported by our findings that
while IL-1b augmented the degradation of IkBa protein (an
important event in the activation of classical pathway), it did not
affect the levels of p100 and p52 proteins (Figure 7B). In future
studies, it will be interesting to investigate which pathway mediates
the loss of skeletal muscle mass in response to TNF-a.
TNF-a affects multiple molecular pathways and gene
networks in C2C12 myotubes
The Ingenuity pathway analysis (IPA) of the selected genes that
are differentially regulated by TNF treatment in C2C12 myotubes
showed that it affects the activation of multiple canonical pathways
in skeletal muscle cells. The major pathways affected by TNF-a
are those involved in initiation and manifestation of fibrosis,
oxidative stress, and mitochondrial dysfunction (Figure 8).
Interestingly, it has now become increasingly clear that skeletal
muscle wasting in both chronic diseases and disuse conditions
leads to the up-regulation of these pathways in skeletal muscle
[10,23,60,61] suggesting that TNF-a may be one of the important
stimuli for their activation in catabolic conditions. Our analysis
also showed that TNF-a affects the pathway involved in
neurological disease and organismal injury (Figure 9) and nervous
system development, cell cycle and cancer (Figure 10). Though
TNF and TWEAK are two cytokines that share similar functions,
it is of considerable importance that they affect distinct gene
networks. Our previous studies showed the up-regulation of
proteasomal pathway by TWEAK [28] but not by TNF-a. These
studies further indicate that different inflammatory cytokines may
regulate different set of molecular pathways in skeletal muscle and
coordinated activation of these pathways may be responsible for
the loss of skeletal muscle mass and myopathy in a particular
disease state.
Conclusions: The data presented in this study suggest that
TNF-a affects the expression of specific set of genes which are
involved in the regulation of various molecular pathways/
processes including extracellular matrix degradation, NF-kB
signaling, Notch1 signaling, chemokine network, apoptosis, and
muscle cell proliferation and differentiation. The study has also
identified the activation of alternative NF-kB signaling pathway in
C2C12 myotubes in response to TNF-a. The present study will
provide strong basis for further delineating the molecular




Dulbecco’s modified Eagle’s medium (DMEM), fetal bovine
serum (FBS), Horse serum was purchased from Sigma Chemical
Company (St. Louis, MO). Recombinant mouse TNF-a protein
and antibodies against MMP-9 and TIMP2 were purchased from
R&D Systems (Minneapolis, MN). Antibodies against IkBa, p50,
p65, c-Jun, phospho-p52, phospho-IkB, phospho-IKKa and
Notch1 were purchased from Santa Cruz Biotechnology (San
Diego, CA). Tubulin, p52/100, RelB, IKKa, IKKb and NFkB2
antibodies were obtained from Cell Signaling Technology
(Beverly, MA). NF-kB consensus oligonucleotides and Dual-
Luciferase assay kits were purchased from Promega (Madison,
WI). Primers for PCR were synthesized by Integrated DNA
Technologies (Coralville, IA) or Sigma-Genosys (Woodlands, TX).
32P-c-ATP was obtained from MP Biomedicals (Solon, OH).
Cell Culture
C2C12 myoblastic cell line was obtained from American Type
Culture Collection (Rockville, MD). These cells were grown in
Dulbecco’s modified Eagle’s Medium (DMEM) containing 20%
fetal bovine serum. C2C12 myoblasts were differentiated into
myotubes by incubation in differentiation medium (DM, 2% horse
serum in DMEM) for 96h as described [47,62]. Myotubes were
maintained in DM and medium was changed every 48h.
cDNA Microarray
Total RNA was isolated from control and TNF-treated C2C12
myotubes using the Agilent total RNA isolation kit (Agilent
Technologies, Palo Alto, CA). Any contaminating DNA was
removed using DNA-free
TM kit from Ambion (Ambion, Austin,
TX). The total RNA concentration was determined by NanoDrop
spectrophotometer, and RNA quality was determined by 18S/28S
ribosomal peak intensity on an Agilent Bioanalyzer. RNA samples
from five wells per condition were separately subjected to
microarray analyses.. Custom cDNA slides were spotted with
Oligator ‘‘MEEBO’’ mouse genome set with 38,467 cDNA probes
(Illumina, Inc., San Diego, CA), which allows interrogation of
25,000 genes. A Q-Array2 robot (Genetix) was used for spotting.
The array includes positive controls, doped sequences, and random
sequences to insure correct gene expression values were obtained
from each array. A total of 250 ng RNA was used to synthesize
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Linear Application Kit (Agilent). The microarray slides were
scanned using a GSI Lumonics ScanArray 4200A Genepix scanner
(Axon). The image intensities were analyzed using the ImaGene 5.6
software (Biodiscovery, Inc., El Segundo, CA). Expression analysis
of microarray experiments was performed with GeneSpring 7.1
(Silicon Genetics, Palo Alto, CA) using the raw intensity data
generated by the ImaGene software. Local background was
subtracted from total signal intensities and was used as intensity
measures. The data were normalized using per spot and per chip
LOWESS normalization. Data analysis was performed using SAS
(SAS Institute, Cary, NC), R and Q value software. The probe sets
with absent calls across all samples were removed to reduce the
multiple-testing problem. The expression levels were normalized to
thechip medianand logtransformed.Two–wayANOVAtestswere
carried out to identify differentially expressed genes. For each probe
set, the model yijk~mzaizbjzcijzeijk was fit, where yijk is the
log-transformed expression level of the kth chip in the ith treatment
and the jth replicate. The variable m represents the grand mean
expression, ai is the effect due to the treatment, bj is the effect due to
the replicate, cij is the interaction effect between treatment and
replicate, and eijk is an error term, which is assumed to be normally
distributed with mean 0 and variance s2. Q values computed using
Q valuesoftware indicatesthefalsedetectionrateforeachprobeset.
Ratio comparison was performed by dividing expression levels in
TNF-treated myotubes with the expression levels in untreated
myotubes. Functional classification of select probe sets was
performed at NIH DAVID server (http://apps1.niaid.nih.gov/
david/upload.asp). Volcano plots were prepared using the R
program. The complete raw and normalized microarray data have
been submitted in MIAME compliant ArrayExpress (http://www.
ebi.ac.uk/microarray-as/ae/) database with accession number
E-MEXP-2592.
Quantitative Real-Time-PCR (QRT-PCR)
T h ee x p r e s s i o no ft h ed i f f e r e n t i a l l yr e g u l a t e dg e n e sf r o mt h e
microarray data set was validated using QRT-PCR as previously
described [47,62]. Briefly, purified RNA (1 mg) from myotubes
was used to synthesize first strand cDNA by reverse transcription
system using Ambion’s oligo-dT primer and Qiagen’s Omnis-
cript reverse transcriptase according to the manufacturer’s
instructions. The first strand cDNA reaction (0.5 ml) was
subjected to real time PCR amplification using gene specific
primers. The primers were designed using Vector NTI Xi
software (Invitrogen).
Quantification of mRNA was done using the SYBR Green
method on ABI Prism 7300 Sequence Detection System (Applied
Biosystems, Foster City, CA). Approximately 25ml of reaction
volume was used for the real time PCR assay that consisted of 26
(12.5ml) Brilliant SYBR Green QPCR Master Mix (Applied
Biosystems), 400nM of primers (0.5 ml each from the stock), 11ml
of water, and 0.5 ml of template. The thermal conditions consisted
of an initial denaturation at 95uC for 10 minutes followed by 40
cycles of denaturation at 95uC for 15 sec, annealing and extension
at 60uC for 1 minute, and a final step melting curve of 95uC for
15 sec, 60uC for 15 sec, and 95uC for 15 sec. All reactions were
carried out in triplicate to reduce variation. The data was analyzed
using SDS software version 2.0, and the results were exported to
Microsoft Excel for further analysis. Data normalization was
accomplished using the endogenous control b-actin and the
normalized values were subjected to a 2
2DDCt formula to calculate
the fold change between the control and experimental groups. The
formula and its derivations were obtained from the ABI Prism
7900 Sequence Detection System user guide.
Pathways and Networks Analyses
Relative levels of gene expression were first computed with
GeneSpring 7.1 to obtain data sets of differentially regulated genes
based on cut-off values of 5% error rate (p,0.05, determined by t-
test with Benjamini and Hochberg Multiple Testing Correction).
These data sets included up and down regulated genes when
C2C12 myotubes were treated with TNF. The second step of
analysis consisted of identifying canonical pathways. Tab separat-
ed (txt) files containing Accession IDs and symbols derived from
MEEBO genome set and the normalized expression ratios were
then uploaded to Ingenuity Pathways Analysis. Ingenuity Path-
ways Analysis is a web-delivered bioinformatics tool (IPA 5.0,
http://www.ingenuity.com) to identify pathways and functional
networks. IPA knowledge database is generated from the peer-
reviewed scientific publications that enables discovery. The
Accession IDs and symbols in each data set were queried against
all genes stored in the IPA knowledge database for pathway
analysis. Canonical pathways analysis identified the pathways from
IPA library of canonical pathways that were most significant to the
data set. The significance of the association between the data set
and the canonical pathways was measured in 2 ways: 1) A ratio of
the number of genes from the data set that map to the pathway
divided by the total number of genes that map to the canonical
pathway is displayed. 2) Fisher’s exact test was used to calculate a
p-value determining the probability that the association between
the genes in the data set and the canonical pathway is explained by
chance alone.
Western Blot
Western blotting was performed to measure the levels of
different proteins using a standard protocol in our laboratory as
described [32,47,62].The dilution of primary antibody was as
follows: anti-IkB (1:1000), anti-NFkB2 (1:500), anti-MMP-9
(1:2000), anti-p52/100 (1:1000), anti-p50 (1:1000), anti-RelB
(1:1000), anti-phospho IKKa (1:500) anti-Notch1 (1:1000), anti-
TIMP2 (1:500), and anti-tubulin (1:3000). Immunoblots were
quantified using ImageQuant TL software (GE Healthcare).
Electrophoretic mobility shift assay (EMSA)
The activation of NF-kB transcription factors was measured by
EMSA. A detailed procedure for the preparation of nuclear and
cytoplasmic extracts and EMSA has been described previously
[47].
Statistical Analysis
Methods used for statistical analysis of the cDNA microarray
has been described above. For all other studies, results were
expressed as mean 6 SD. The Student’s t test was used to
compare quantitative data populations with normal distributions
and equal variance. A value of P,0.05 was considered statistically
significant unless otherwise specified.
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